HUMANIGEN INC (HGEN) Stock Price, Quote, News and Overview
NASDAQ:HGEN - Nasdaq - US4448632038 - Common Stock - Currency: USD
HGEN Quote, Performance and Key Statistics
0.0361
-0.16 (-81.12%)
The current stock price of HGEN is 0.0361 USD. In the past month the price decreased by -76.06%. In the past year, price decreased by -90.16%.
HGEN Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About HGEN
Company Profile
Humanigen, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Short Hills, New Jersey and currently employs 6 full-time employees. The company went IPO on 2013-01-30. The firm is engaged in developing its portfolio of proprietary Humaneered anti-inflammatory immunology and immuno-oncology monoclonal antibodies. Its Humaneered technology platform is a method for converting existing antibodies (typically murine) into engineered, high-affinity human antibodies designed for therapeutic use, particularly with acute and chronic conditions. Its product candidate, lenzilumab, and its other product candidate, ifabotuzumab (iFab), are Humaneered monoclonal antibodies are Humaneered monoclonal antibodies. lenzilumab is used as a therapeutic for chronic myelomonocytic leukemia; for the prevention of acute graft versus host disease; and as a prophylactic companion for certain chimeric antigen receptor therapy (CAR-T) programs. The firm has developed or in-licensed targets or research antibodies, typically from academic institutions, and then applied its Humaneered technology to optimize them.
Company Info
HUMANIGEN INC
830 Morris Turnpike, 4th Floor
Short Hills NEW JERSEY 94010 US
CEO: Cameron Durrant
Employees: 6
Company Website: https://www.humanigen.com/
Phone: 19732003100.0
HUMANIGEN INC / HGEN FAQ
What is the stock price of HUMANIGEN INC today?
The current stock price of HGEN is 0.0361 USD. The price decreased by -81.12% in the last trading session.
What is the ticker symbol for HUMANIGEN INC stock?
The exchange symbol of HUMANIGEN INC is HGEN and it is listed on the Nasdaq exchange.
On which exchange is HGEN stock listed?
HGEN stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for HUMANIGEN INC stock?
6 analysts have analysed HGEN and the average price target is 0.15 USD. This implies a price increase of 323.82% is expected in the next year compared to the current price of 0.0361. Check the HUMANIGEN INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is HUMANIGEN INC worth?
HUMANIGEN INC (HGEN) has a market capitalization of 4.30M USD. This makes HGEN a Nano Cap stock.
How many employees does HUMANIGEN INC have?
HUMANIGEN INC (HGEN) currently has 6 employees.
Is HUMANIGEN INC (HGEN) expected to grow?
The Revenue of HUMANIGEN INC (HGEN) is expected to decline by -91.42% in the next year. Check the estimates tab for more information on the HGEN EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy HUMANIGEN INC (HGEN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of HGEN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of HGEN, evaluating the profitability, health, valuation and growth aspects
- HUMANIGEN INC (HGEN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- HUMANIGEN INC (HGEN) Sales and EPS estimates to see what analysts future expectations are.
- HUMANIGEN INC (HGEN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- HUMANIGEN INC (HGEN) Insider and Institutional Ownership to learn about the owners and their transactions.
- HUMANIGEN INC (HGEN) Stock Chart to make your own analysis
- HUMANIGEN INC (HGEN) Latest news and press-releases to stay up to date.
Does HUMANIGEN INC (HGEN) stock pay dividends?
HGEN does not pay a dividend.
When does HUMANIGEN INC (HGEN) report earnings?
HUMANIGEN INC (HGEN) will report earnings on 2023-08-10.
What is the Price/Earnings (PE) ratio of HUMANIGEN INC (HGEN)?
HUMANIGEN INC (HGEN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.65).
HGEN Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to HGEN. When comparing the yearly performance of all stocks, HGEN is a bad performer in the overall market: 99.57% of all stocks are doing better.
HGEN Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to HGEN. HGEN may be in some trouble as it scores bad on both profitability and health.
HGEN Financial Highlights
Over the last trailing twelve months HGEN reported a non-GAAP Earnings per Share(EPS) of -0.65. The EPS increased by 79.5% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
HGEN Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 43% to HGEN. The Buy consensus is the average rating of analysts ratings from 6 analysts.
For the next year, analysts expect an EPS growth of 83.55% and a revenue growth -91.42% for HGEN